首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1735607

2026 年至 2032 年疫苗市场规模（依疫苗类型、目标人口、通路和地区划分）

Vaccine Market Size By Type of Vaccine, By Target Population, By Channel of Distribution, And Region For 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2026-2032年疫苗市场评估

2024年，疫苗市场规模为463亿美元，预计2032年将成长至704亿美元，预测期内复合年增长率为8.11%。随着大众对疫苗可预防疾病的认识不断提高，以及民众对公共卫生的重视程度不断提高，疫苗市场的需求正在成长。新冠疫情凸显了疫苗接种在控制传染病的重要性，并促使人们进一步研发新型疫苗。此外，政府对疫苗接种计画的资金投入和支持力度不断加大，也有助于推动市场扩张。

此外，疫苗需求正从感染疾病扩展到癌症和其他慢性疾病疫苗。这种转变，加上疫苗研发和给药技术的进步，预计将支撑疫苗市场未来的成长。

疫苗市场定义/概述

疫苗是生物製药，用于诱发针对特定感染疾病的适应性免疫。它们通常由病原体的无害成分组成，例如减毒或灭活的病毒或遗传物质片段。接种疫苗后，免疫系统会识别病原体，并在再次遇到病原体时发动攻击。疫苗可以预防疾病、降低感染率并建立群体免疫力，保护因健康状况而无法接种疫苗的人。

疫苗接种的原理是引入病原体的无害成分，例如减毒或灭活的病原体或其遗传密码片段，从而增强免疫系统，使其能够在将来再次遇到病毒时快速有效地做出反应。疫苗接种有助于避免集体爆发，保护易感族群，并改善公共卫生。

疫苗接种的未来还包括个人化医疗的进步，即根据个人基因图谱量身定制疫苗，以增强疫苗的有效性。 COVID-19 疫苗中展示的 mRNA 技术也可能被用于治疗其他感染疾病和癌症。此外，人们正在尝试生产针对流感等疾病的通用疫苗，这可能会提供更强大的保护。

预防保健意识的不断提高如何促进疫苗市场的扩张？

预防保健意识的不断增强，促进了疫苗业务的扩张，因为它鼓励人们采取积极主动的健康管理方式。随着越来越多的资料显示疫苗接种在预防感染疾病具有益处，人们更有可能为自己和家人接种疫苗。公共卫生宣传活动和教育计画提高了人们对疫苗与疾病预防之间关联的认识，从而增加了不同人群对疫苗的需求。这种预防趋势鼓励人们优先考虑自身健康，从而提高了疫苗接种率并扩大了市场。

此外，对预防性医疗保健的关注促使政府和企业增加了对疫苗研发的投资。对mRNA疫苗和病毒载体平台等新型疫苗技术的资助正在推动该领域的进步。随着新疫苗的研发和上市，公众兴趣日益浓厚，需求不断增长，疫苗产业也随之扩张。对预防性干预措施的关注最终将减轻感染疾病的负担，并改善整体公共卫生状况。

疫苗研发成本高是否会阻碍疫苗市场的成长？

高昂的疫苗开发成本限制了能够投资研发和生产的公司数量，严重限制了疫苗业务的扩张。开发一种新疫苗需要大量的资金投入，用于广泛的研究、临床试验和合规性。这个过程可能需要数年时间，并且存在很大的不确定性，这使得中小企业难以与大型製药公司竞争。因此，进入市场的新疫苗数量可能会减少，从而减缓整体成长并限制消费者的选择。

此外，疫苗生产成本的上升可能会限制疫苗的取得，尤其是在中低收入国家。运输和储存疫苗需要低温运输物流，这会增加成本并使分发工作更加复杂。如此高成本结构可能会阻碍政府和医疗体系建立全面的疫苗接种计划，阻碍感染疾病控制工作，并限制市场的成长潜力。

The vaccine market size was valued at USD 46.3 Billion in 2024 and is projected to grow 70.4 Billion by 2032, exhibiting a CAGR of 8.11% during the forecast period. The vaccine market is witnessing increased demand as people become more aware of vaccine-preventable diseases and place a greater emphasis on public health. The COVID-19 pandemic highlighted the necessity of vaccination in suppressing epidemics, prompting further research and development of new vaccines. Furthermore, increased government funding and support for immunization programs are fuelling market expansion.

Furthermore, vaccination demand is growing beyond infectious disorders to include therapeutic vaccines for cancer and other chronic illnesses. This transition together with technological advances in vaccine development and delivery technologies is projected to support the vaccine market's growth in the years ahead.

Vaccine Market: Definition/ Overview

A vaccination is a biological preparation that induces acquired immunity to a particular infectious disease. It usually comprises a harmless component of the pathogen such as a weakened or inactivated virus or a fragment of its genetic material. When vaccines are delivered, they stimulate the immune system to recognize and attack the pathogen if it is encountered again. Vaccination prevents illnesses, lowers transmission, and adds to herd immunity protecting people who are unable to be vaccinated due to medical conditions.

They function by introducing an innocuous pathogen component such as a weakened or inactivated form or a fragment of its genetic code. This exposure prepares the immune system to respond rapidly and efficiently if the body encounters the virus again in the future. Vaccination helps avoid outbreaks, protects vulnerable populations, and improves public health.

The future of vaccinations includes advances in personalized medicine in which immunizations are tailored to individual genetic profiles for increased efficacy. MRNA technology as demonstrated by COVID-19 vaccines will most likely be developed to treat other infectious diseases and cancer. In addition, attempts are underway to produce universal vaccinations for diseases such as influenza intending to provide greater protection.

How does Growing Awareness of Preventative Healthcare Contribute to the Expansion of the Vaccine Market?

A growing understanding of preventative healthcare helps to expand the vaccine business by encouraging a proactive approach to health management. As people learn more about the benefits of vaccination in preventing infectious diseases, they are more likely to seek immunizations for themselves and their families. Public health campaigns and educational programs have expanded awareness of the link between vaccines and illness prevention, resulting in increased demand for vaccines across various populations. This trend toward prevention encourages people to prioritize their health, which leads to higher vaccination rates and a larger market.

Furthermore, the emphasis on preventative healthcare has resulted in increasing government and corporate sector investment in vaccine research and development. Funding for novel vaccination technologies such as mRNA vaccines and viral vector platforms has spurred progress in this field. As new vaccines are developed and presented, they pique public interest, increasing demand and extending the vaccination industry. This emphasis on prevention interventions eventually reduces the burden of infectious diseases improving overall public health outcomes.

How Does the High Cost of Vaccine Development Serve as a Restraint on the Growth of the Vaccine Market?

The high cost of vaccine development severely limits the expansion of the vaccine business by limiting the number of companies capable of investing in research and production. Developing a novel vaccination necessitates significant financial investment for extensive research, clinical trials, and regulatory compliance. These processes can take years and involve a great deal of uncertainty making it difficult for smaller enterprises to compete with major pharmaceutical giants. As a result, fewer novel vaccines enter the market, potentially slowing overall growth and limiting customer alternatives.

Furthermore, the expense of vaccine manufacture might drive up costs, limiting access, especially in low- and middle-income nations. Transporting and storing vaccines requires cold chain logistics which raises costs and complicates distribution efforts. This high-cost structure may discourage governments and healthcare systems from establishing comprehensive immunization programs hamper efforts to control infectious illnesses, and restrict the market's potential for growth.

Category-Wise Acumens

How do Government Policies and Health Organizations Influence the Uptake of Pediatric Vaccinations?

Pediatric vaccines dominate the vaccine market owing to the increased need for immunization against numerous infectious diseases among children. Measles, mumps, rubella, polio, and hepatitis are all preventable diseases that require vaccination in childhood. Governments and health organizations prioritize kid immunization programs to ensure population health, resulting in broad vaccination campaigns. The implementation of routine vaccination schedules and mandated immunization laws in several countries has increased the demand for pediatric vaccinations.

Furthermore, as parents become more aware of the benefits of vaccinating their children, pediatric vaccinations have grown in popularity. Campaigns highlighting the value of immunization and addressing vaccine hesitancy have increased public trust in vaccination programs. As a result, pharmaceutical companies and healthcare providers are expanding their focus on producing and marketing pediatric vaccinations, resulting in large R&D investments. This emphasis guarantees that pediatric vaccinations remain an important component of the overall vaccine industry.

How do Healthcare Professionals in Hospitals and Clinics Educate Patients about the Benefits and Potential Side Effects of Vaccines?

Hospitals and clinics dominate the vaccine industry because of their critical role in delivering complete healthcare services. These facilities are key places of care for immunizations which are frequently included in ordinary healthcare practices. They provide a controlled environment for immunizations assuring safe storage, handling, and administration. Furthermore, hospitals and clinics frequently have access to a large patient population making it easier to run vaccination programs and campaigns efficiently.

Furthermore, hospitals and clinics are staffed with qualified healthcare experts who can educate people on the benefits of vaccines, address concerns, and manage potential adverse effects. Their established infrastructure facilitates the coordination of immunization schedules, record-keeping, and follow-up care. The emphasis on preventive healthcare in these contexts, particularly in reaction to epidemics or public health campaigns strengthens their position in the vaccine market by assuring high vaccination rates and successful immunization programs.

Country/Region-wise Acumens

How do Strong Research and Development Capabilities Impact the Diversity of Vaccines Available in the North American Region?

North America dominates the vaccination industry owing to its advanced healthcare infrastructure, strong research and development capabilities, and considerable financial investments in biotechnology. The region is home to major pharmaceutical businesses and research organizations that promote innovation and manufacture a diverse range of vaccines. Government support such as funding for vaccine development and public health programs boosts market growth as demonstrated during the COVID-19 pandemic.

Furthermore, North America has a strong distribution network that ensures vaccinations are stored and distributed under optimal circumstances, thereby preserving their potency. Public awareness campaigns and educational tools efficiently communicate the benefits of vaccines which boosts public trust. The region's response to recent health emergencies such as the COVID-19 pandemic, demonstrated its ability to quickly mobilize resources maintaining its leadership in the worldwide vaccination market.

How has the COVID-19 Pandemic Influenced Government Investments in Healthcare Infrastructure and Vaccination Initiatives in the Asia-Pacific Region?

Asia Pacific is the fastest-growing region in the vaccine market owing to a combination of reasons such as increasing population, rising healthcare expenditure, and increased awareness of the benefits of immunization. The region has a vast and diversified population which increases the demand for vaccines to treat a variety of infectious diseases. Furthermore, governments are investing heavily in healthcare infrastructure and vaccination initiatives to improve public health outcomes, particularly considering recent global health disasters such as the COVID-19 pandemic.

Furthermore, the rapid development of biotechnology and pharmaceutical industries in countries such as China and India improved vaccine production capacities and innovation. Collaborations between the public and private sectors accelerate research and development, resulting in the launch of new vaccinations. Furthermore, supporting government policies and initiatives focused on increasing immunization coverage and boosting healthcare access are driving market expansion in the Asia Pacific establishing the region as a worldwide vaccine industry leader.

Competitive Landscape

The Vaccine Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the vaccine market include:

GSK plc, Merck & Co., Pfizer Inc., Sanofi, CSL Limited, Johnson & Johnson Services, AstraZeneca, Serum Institute of India Pvt Ltd, Bharat Biotech International Limited, Sinovac Biotech Ltd.

Latest Developments

In May 2024, Novavax and Sanofi disclosed a co-exclusive licensing agreement to co-commercialize a COVID-19 vaccine and collaborate on developing novel combination vaccines for COVID-19 and influenza. This strategic partnership allows both companies to leverage their respective expertise and resources to bring innovative vaccine solutions to the market. By joining forces, Novavax and Sanofi aim to enhance their competitive position in the rapidly evolving landscape of vaccine development and distribution.
In April 2023, Pfizer announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.

1 INTRODUCTION OF GLOBAL VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL VACCINE MARKET, BY TYPE OF VACCINE

5.1 Overview
5.2 Preventive Vaccines
5.3 Therapeutic Vaccines
5.4 Recombinant Vaccines
5.5 Conjugate vaccines

6 GLOBAL VACCINE MARKET, BY TARGET POPULATION

6.1 Overview
6.2 Paediatric vaccines
6.3 Adult Vaccines
6.4 Vaccines for the Elderly
6.5 Travel vaccinations

7 GLOBAL VACCINE MARKET, BY CHANNEL OF DISTRIBUTION

7.1 Overview
7.2 Hospitals and Clinics
7.3 Retail Pharmacies
7.4 Government Programmes
7.5 Internet pharmacies

8 GLOBAL VACCINE MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL VACCINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 GSK plc
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Merck & Co.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Pfizer Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Sanofi
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 CSL Limited
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Johnson & Johnson Services
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 AstraZeneca
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Serum Institute of India Pvt Ltd
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bharat Biotech International Limited
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Sinovac Biotech Ltd
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 Appendix

11.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年疫苗市场规模（依疫苗类型、目标人口、通路和地区划分）

Vaccine Market Size By Type of Vaccine, By Target Population, By Channel of Distribution, And Region For 2026-2032

2026-2032年疫苗市场评估

预防保健意识的不断提高如何促进疫苗市场的扩张？

疫苗研发成本高是否会阻碍疫苗市场的成长？

目录

第一章 全球疫苗市场简介

第二章执行摘要

第三章：已验证的市场研究调查方法

第四章全球疫苗市场展望

5. 全球疫苗市场（依疫苗类型）

6. 全球疫苗市场（依目标人口）

7. 全球疫苗市场（依分销管道）

8. 全球疫苗市场（按地区）

第九章全球疫苗市场的竞争格局

第十章 公司简介

第十一章 附录

Vaccine Market Valuation - 2026-2032